Regencell’s 9,800% stock surge baffles analysts despite zero revenue
Regencell Bioscience Holdings has seen its share price soar this year, rising by 9,800% since its 2021 market debut on Yahoo Finance. The company's market value now exceeds $6 billion, despite reporting no revenue in recent years. Investors have rushed to back its research into Traditional Chinese Medicine for conditions like ADHD and autism, which is a hot topic in the stock market today.
The Hong Kong-listed firm went public in 2021 but has yet to bring any commercial products to market. Financial records show zero revenue from 2021 through 2025, alongside annual net losses every year.
Despite its financial losses and lack of revenue, Regencell's market capitalisation has climbed past $6 billion. The surge reflects strong investor confidence in its research pipeline. The company continues to focus on neurocognitive disorder treatments without any confirmed commercial success in the stock market.
